白细胞介素-18联合肾损伤分子-1预测ICU行连续性肾脏替代治疗急性肾损伤患者28天死亡
前瞻性观察研究纳入河北医科大学第四医院ICU 2017年6月至2018年2月连续行CRRT的AKI危重患者30例(AKI 2期12例、3期18例),CRRT前采集尿标本测IL-18与KIM-1并随访28天。AKI 3期组尿KIM-1显著高于2期组,尿IL-18无显著差异。AKI 2期组28天全因病死率显著低于3期组(16.7% vs 66.7%)。ROC分析示尿IL-18联合KIM-1预测28天死亡的AUC为0.786,敏感度50.0%、特异度100%。作者认为尿IL-18联合KIM-1对AKI预后有较高预测价值,AKI 2期启动CRRT较3期可显著降低28天病死率。
要点
- AKI 2期启动CRRT者28天全因病死率16.7%(2/12),显著低于AKI 3期启动者的66.7%(12/18)(P<0.05)。
- CRRT前尿KIM-1在AKI 3期组显著高于2期组[ng/L:6 195.6(5 892.6,7 935.4)vs. 5 487.5(4 769.8,6 353.4),P<0.01]。
- CRRT前尿IL-18在AKI 2期与3期组间无统计学差异[ng/L:52.1(48.1,62.6)vs. 53.9(52.0,57.2),P>0.05]。
- 尿IL-18联合KIM-1预测28天死亡AUC 0.786(95%CI 0.598-0.914,P=0.001),敏感度50.0%、特异度100%。
- 尿IL-18单独预测价值小,KIM-1有一定预测价值,联合检测预测价值更大(原文结论)。
适用人群与场景
- 河北医科大学第四医院ICU连续收治、行CRRT的AKI危重患者,按KDIGO分为AKI 2期与3期。
- 排除ICU停留不足3天、慢性肾脏病、腹腔内高压(IAH)、采尿前4小时内使用利尿剂或已行肾脏替代治疗者。
诊断标准与关键阈值
- 按KDIGO指南将患者分为AKI 2期组与AKI 3期组。
- CRRT前采集尿标本,用酶联免疫吸附试验(ELISA)测定尿IL-18与KIM-1水平。
研究设计与关键结果
- 前瞻性观察研究,最终纳入30例,其中AKI 2期12例、AKI 3期18例;两组性别、年龄、身高、体重、基础生命体征、基础肾功能及疾病严重程度等基本特征无显著差异。
- AKI 3期组尿KIM-1显著高于AKI 2期组[ng/L:6 195.6(5 892.6,7 935.4)vs. 5 487.5(4 769.8,6 353.4),P<0.01],尿IL-18两组无统计学差异[ng/L:52.1(48.1,62.6)vs. 53.9(52.0,57.2),P>0.05]。
- 28天全因病死率AKI 2期组16.7%(2/12)显著低于AKI 3期组66.7%(12/18),P<0.05。
- ROC曲线示尿IL-18单独预测价值小、KIM-1有一定预测价值,联合检测预测价值更大,AUC 0.786(95%CI 0.598-0.914,P=0.001),敏感度50.0%、特异度100%。
证据类型、等级与局限
- 证据类型:前瞻性观察研究,单中心,样本量30例,随访28天。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尿IL-18联合尿KIM-1对AKI患者预后有较高预测价值(AUC 0.786,敏感度50.0%、特异度100%)。
- 作者认为,对AKI危重患者,在AKI 2期启动CRRT治疗较AKI 3期可显著降低28天病死率(16.7% vs 66.7%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the predict value of interleukin-18 (IL-18) combine with kidney injury molecule-1 (KIM-1) on 28-day mortality in patients with acute kidney injury (AKI) undergoing continuous renal replacement therapy (CRRT) in intensive care unit (ICU), and to look for the start time of CRRT.
METHODS: A prospective observational study was conducted. The consecutive AKI critical patients who underwent CRRT from June 2017 to February 2018 admitted to ICU of the Fourth Hospital of Hebei Medical University were enrolled. Patients were divided into AKI 2 stage and AKI 3 stage groups according to the guidelines for Kidney Disease: Improving Global Outcomes (KDIGO). Basic vital signs were recorded for all enrolled patients, and ventilator parameters were recorded for patients on ventilation. Urine specimens were collected before CRRT, and IL-18 and KIM-1 levels were measured by enzyme-linked immunosorbent assay (ELISA). The patients were followed up for 28 days. The receiver operating characteristic (ROC) curve was drawn to evaluate the predictive value of urinary IL-18 and KIM-1 for prognosis.
RESULTS: During the study period, 38 patients were treated. The patients with ICU stayed for less than 3 days, chronic obstructive kidney disease, intra-abdominal hypertension (IAH), diuretics usage within 4 hours or renal replacement therapy before urine collection were excluded. Finally, 30 patients were enrolled, including 12 patients with AKI phase 2 and 18 patients with AKI phase 3. There was no significant difference in basic medical characteristics such as gender, age, height, weight, basic vital signs, basic renal function, or severity of disease between AKI 2 stage and AKI 3 stage groups. Compared with the AKI 2 stage group, the level of urine KIM-1 in the AKI 3 stage group was significantly increased [ng/L: 6 195.6 (5 892.6, 7 935.4) vs. 5 487.5 (4 769.8, 6 353.4), P < 0.01], but urine IL-18 level was not statistically significant [ng/L: 52.1 (48.1, 62.6) vs. 53.9 (52.0, 57.2), P > 0.05]. All patients were followed up for 28 days. The 28-day all-cause mortality rate of AKI 2 stage group was significantly lower than that of AKI 3 stage group [16.7% (2/12) vs. 66.7% (12/18), P < 0.05]. ROC curve analysis showed that urinary IL-18 had a small predictive value for the 28-day mortality of AKI patients undergoing CRRT, and KIM-1 had a certain predictive value, and the combined value of the combined detection was greater, and the area under ROC curve (AUC) was 0.786 [95% confidence interval (95%CI) = 0.598-0.914, P = 0.001] with a sensitivity of 50.0% and a specificity of 100%.
CONCLUSIONS: Urine IL-18 combined with urine KIM-1 has a high predictive value for the prognosis of patients with AKI. For critically ill patients with AKI, initiation of CRRT treatment in AKI 2 stage can significantly reduce the 28-day mortality as compared with that in AKI 3 stage.
参考来源
- Huo Y, Zhang K, Hu Z, et al. [Interleukin-18 combined with kidney injury molecule-1 predict 28-day mortality in patients with acute kidney injury treated with continuous renal replacement therapy in intensive care unit]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31441405. doi:10.3760/cma.j.issn.2095-4352.2019.07.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。